Suppr超能文献

林奇综合征中家族史和错配修复基因突变与癌症风险的关系。

Cancer-risk by family history and mismatch-repair mutation in Lynch syndrome.

机构信息

Department of Gastroenterology, Portuguese Oncology Institute of Porto, Porto, Portugal.

CINTESIS (Center for Health Technology and Services Research), Faculty of Medicine, University of Porto, Porto, Portugal.

出版信息

Scand J Gastroenterol. 2020 Jun;55(6):701-705. doi: 10.1080/00365521.2020.1766553. Epub 2020 May 24.

Abstract

Surveillance of Lynch syndrome (LS) is recommended to reduce cancer-risk. There is an increased awareness that cancer-risk may vary with mismatch-repair mutation and family history. However, gene-specific and family-specific surveillance are not recommended. Therefore, we aimed to estimate the cumulative incidence of lesions and to assess the cancer-risk by family history and mismatch-repair mutation (MMR). Single-centre retrospective cohort of all individuals ( = 241) in a specialized institution was conducted. Forty-eight percent of individuals inherited MSH2 mutations, 32% MLH1, 15% MSH6 and 5% PMS2. The calculated cumulative incidence for any cancer increased with age. By age 70, the cumulative incidence for low-risk, high-risk adenomas and CRC was estimated at 66.6%, 57.7% and 25.7%, respectively. By age 70, the cumulative incidence of endometrial cancer (EC), gastric cancer and urinary tract cancer was estimated at 17.3%, 3.3% and 12.6%, respectively. MLH1 and MSH2 mutation carriers had lower mean age of CRC diagnosis than MSH6 and PMS2 [MLH1:44(CI95% 38-50); MSH2:43(CI95% 40-47); MSH6:52(CI95% 45-59); PMS2:46(CI95% 35-57)]. The risk of EC was higher when family history was present (RR = 2.39, CI95%[1.3;4.6]). MSH6 mutation carriers had higher risk of EC comparative to other MMR mutation carriers (RR = 1.9,  = .09). The risk of urinary tract cancer was higher with MSH2 (RR = 8.4, CI95%[2.7;25.9]) and positive family history (RR = 10.8, CI95%[1.4;82.8]). This cohort demonstrates the effectiveness of LS surveillance and suggests possible tailored surveillance strategies by gene mutation and family history.

摘要

林奇综合征(LS)的监测被推荐用于降低癌症风险。人们越来越意识到,癌症风险可能因错配修复突变和家族史而异。然而,不推荐针对特定基因和家族的监测。因此,我们旨在通过家族史和错配修复突变(MMR)来估计病变的累积发生率,并评估癌症风险。对专门机构的所有个体(= 241)进行了单中心回顾性队列研究。48%的个体遗传了 MSH2 突变,32%遗传了 MLH1,15%遗传了 MSH6,5%遗传了 PMS2。任何癌症的累积发生率随年龄增加而增加。到 70 岁时,低危、高危腺瘤和 CRC 的累积发生率估计分别为 66.6%、57.7%和 25.7%。到 70 岁时,子宫内膜癌(EC)、胃癌和泌尿道癌的累积发生率估计分别为 17.3%、3.3%和 12.6%。MLH1 和 MSH2 突变携带者的 CRC 诊断平均年龄低于 MSH6 和 PMS2[MLH1:44(95%CI95% 38-50);MSH2:43(95%CI95% 40-47);MSH6:52(95%CI95% 45-59);PMS2:46(95%CI95% 35-57)]。存在家族史时,EC 的风险更高(RR = 2.39,95%CI[1.3;4.6])。与其他 MMR 突变携带者相比,MSH6 突变携带者 EC 的风险更高(RR = 1.9,=.09)。MSH2 突变(RR = 8.4,95%CI[2.7;25.9])和阳性家族史(RR = 10.8,95%CI[1.4;82.8])会增加泌尿道癌的风险。该队列表明 LS 监测有效,并提示可根据基因突变和家族史制定个性化的监测策略。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验